pharma-2018-posters-abstracts

Pharma 2018

Page 50

E u r o p e a n C o n g r e s s o n

Pharma

A u g u s t 1 3 - 1 4 , 2 0 1 8

P a r i s , F r a n c e

American Journal of Pharmacology and Pharmacotherapeutics

ISSN: 2393-8862

Background:

Liraglutide is an analogue of Glucagon-Like Peptide-1 (GLP-1) which was approved for treatment of type 2 diabetes

mellitus at doses of 1.2 and 1.8 after that was approved at dose of 3.0 mg for treatment of obesity in combination with diet and

exercise. Efficacy of liraglutide for weight loss was studied for diabetic and non-diabetic patients as well. The objective of this

review is to determine if liraglutide is more effective in diabetic versus non diabetic patients.

Methods:

We conducted a systematic review and meta-analysis of randomized clinical trials (RCT) comparing efficacy of

liraglutide 3.0 mg for weight loss among diabetic and non-diabetic patients. We searched PubMed, Ovid Medline, Google Scholar

and Cochrane Library databases relevant published studies in English from Mar’ 2008 until Mar’ 2018. We estimated standard

mean difference (Std. MD) with 95% confidence intervals using random effects model and assessed for heterogeneity (I2).

Results:

We screened a total of 42 studies related to liraglutide efficacy for weight loss from which four studies (with 4678

patients) studies met our inclusion criteria. One of them studied liraglutide efficacy in weight loss in diabetic patients, while the

other three studied liraglutide efficacy in weight loss in non-diabetic patients. Weight loss in non-diabetic patients was statistically

higher (Std. MD 0.80, CI 0.74 to 0.86, [P=0.49I2=0%]

Discussion:

This meta-analysis of RCTs showed that weight loss due to liraglutide use in non-diabetic patients was statistically

higher than it in diabetic patients.

Other:

More trials on diabetic patients using liraglutide for weight loss are required. Also more trials on variant ethnicities are

required.

Liraglutide 3.0 mg for weight loss, is it more

effective in diabetic or non-diabetic patients? A

systematic review and meta-analysis

Shimaa Elsayad Ahmed

Egypt

Am J Pharmacol Pharmacother 2018, Volume 5

DOI: 10.21767/2393-8862-C1-003